Evaluation of the Safety and Efficacy of HK-660S in Patients With Primary Sclerosing Cholangitis
Status:
Active, not recruiting
Trial end date:
2023-07-31
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the improvement of bile duct strictures following
the administration of HK-660S in patients with Primary Sclerosing Cholangitis(PSC).
Percentage of subjects who show improvement of severity of PSC as assessed by Magnetic
Resonance Cholangiopancreatography(MRCP) at Week 12 from baseline, with improvement defined
as a decrease of -1 or more in the MRCP and change of alkaline phosphatase(ALP) level will be
assessed at Week 12 from baseline.